These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 27890174)

  • 1. Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology.
    Cappelli LC; Shah AA; Bingham CO
    Rheum Dis Clin North Am; 2017 Feb; 43(1):65-78. PubMed ID: 27890174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors.
    Tocut M; Brenner R; Zandman-Goddard G
    Autoimmun Rev; 2018 Jun; 17(6):610-616. PubMed ID: 29631064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.
    Kostine M; Truchetet ME; Schaeverbeke T
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii68-vii74. PubMed ID: 31816082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.
    Cappelli LC; Gutierrez AK; Baer AN; Albayda J; Manno RL; Haque U; Lipson EJ; Bleich KB; Shah AA; Naidoo J; Brahmer JR; Le D; Bingham CO
    Ann Rheum Dis; 2017 Jan; 76(1):43-50. PubMed ID: 27307501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of rheumatic adverse events of cancer immunotherapy.
    Reid P; Cappelli LC
    Best Pract Res Clin Rheumatol; 2022 Dec; 36(4):101805. PubMed ID: 36539321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.
    Abdel-Wahab N; Suarez-Almazor ME
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii40-vii48. PubMed ID: 31816084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.
    Melissaropoulos K; Klavdianou K; Filippopoulou A; Kalofonou F; Kalofonos H; Daoussis D
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32403289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spectrum and impact of checkpoint inhibitor-induced irAEs.
    Cappelli LC; Bingham CO
    Nat Rev Rheumatol; 2021 Feb; 17(2):69-70. PubMed ID: 33235330
    [No Abstract]   [Full Text] [Related]  

  • 9. Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy.
    Warner BM; Baer AN; Lipson EJ; Allen C; Hinrichs C; Rajan A; Pelayo E; Beach M; Gulley JL; Madan RA; Feliciano J; Grisius M; Long L; Powers A; Kleiner DE; Cappelli L; Alevizos I
    Oncologist; 2019 Sep; 24(9):1259-1269. PubMed ID: 30996010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors-A 2023 Update.
    Dang QM; Watanabe R; Shiomi M; Fukumoto K; Nobashi TW; Okano T; Yamada S; Hashimoto M
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rheumatological complications of immune checkpoint inhibitor therapy].
    Lazarou I; Fernandez E
    Rev Med Suisse; 2020 Mar; 16(685):504-507. PubMed ID: 32167253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature.
    Cappelli LC; Gutierrez AK; Bingham CO; Shah AA
    Arthritis Care Res (Hoboken); 2017 Nov; 69(11):1751-1763. PubMed ID: 27998041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management.
    Singh N; Shahane A; Sparks JA; Bitoun S; Cappelli LC
    Rheum Dis Clin North Am; 2024 May; 50(2):269-279. PubMed ID: 38670725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheumatological Adverse Events of Cancer Therapy with Immune Checkpoint Inhibitors.
    Cano-Cruz LG; Barrera-Vargas A; Mateos-Soria A; Soto-Perez-de-Celis E; Merayo-Chalico J
    Arch Med Res; 2022 Feb; 53(2):113-121. PubMed ID: 34649738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sicca syndrome following immune checkpoint inhibition.
    Mavragani CP; Moutsopoulos HM
    Clin Immunol; 2020 Aug; 217():108497. PubMed ID: 32531346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
    Kostine M; Finckh A; Bingham CO; Visser K; Leipe J; Schulze-Koops H; Choy EH; Benesova K; Radstake TRDJ; Cope AP; Lambotte O; Gottenberg JE; Allenbach Y; Visser M; Rusthoven C; Thomasen L; Jamal S; Marabelle A; Larkin J; Haanen JBAG; Calabrese LH; Mariette X; Schaeverbeke T
    Ann Rheum Dis; 2021 Jan; 80(1):36-48. PubMed ID: 32327425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sicca syndrome associated with immune checkpoint inhibitor therapy.
    Harris JA; Huang K; Miloslavsky E; Hanna GJ
    Oral Dis; 2022 Nov; 28(8):2083-2092. PubMed ID: 34379884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.
    Cappelli LC; Bingham CO
    Arthritis Rheumatol; 2021 Apr; 73(4):553-565. PubMed ID: 33186490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.
    Leipe J; Mariette X
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii49-vii58. PubMed ID: 31816078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy.
    Abdel-Wahab N; Suarez-Almazor ME
    Expert Rev Clin Immunol; 2024 Aug; 20(8):873-893. PubMed ID: 38400840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.